Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial
Crossref DOI link: https://doi.org/10.1186/s13075-014-0451-y
Published Online: 2014-10-01
Published Print: 2014-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Luciano, Juan V
D’Amico, Francesco
Cerdà-Lafont, Marta
Peñarrubia-María, María T
Knapp, Martin
Cuesta-Vargas, Antonio I
Serrano-Blanco, Antoni
García-Campayo, Javier
License valid from 2014-10-01